<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-161015</identifier>
<setSpec>0214-9168</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Interplay between HSP90 and Nrf2 pathways in diabetes-associated atherosclerosis</dc:title>
<dc:description xml:lang="en">Introduction: Oxidative stress and inflammation are determinant processes in the development of diabetic vascular complications. Heat shock protein 90 (HSP90) overexpression in atherosclerotic plaques plays a role in sustaining inflammatory mechanisms, and its specific inhibition prevents atherosclerosis. The present work investigates, in a mouse model of diabetes-driven atherosclerosis, whether atheroprotection by pharmacological HSP90 inhibition is accomplished by bolstering antioxidant defense mechanisms headed by nuclear factor erythroid-derived 2-like 2 (Nrf2). Methods: Streptozotocin-induced diabetic apolipoprotein E-deficient mice were randomized to receive vehicle or HSP90 inhibitor (17-dimethylaminoethylamino-17-demethoxygeldanamycin, 4mg/kg) for 10 weeks. Aortic root sections were analyzed for plaque size and composition, transcription factor activity, and expression of inflammatory and antioxidant markers. In vitro studies were performed in murine macrophages cultured under hyperglycemic conditions. Results: Treatment with HSP90 inhibitor promoted the activation of Nrf2 in the aortic tissue of diabetic mice (predominantly localized in macrophages and smooth muscle cells) and also in cultured cells. Nrf2 induction was associated with a concomitant inhibition of nuclear factor-¿B (NF-¿B) in atherosclerotic plaques, thus resulting in a significant reduction in lesion size and inflammatory component (leukocytes and cytokines). Furthermore, atheroprotection by HSP90 inhibition was linked to the induction of cytoprotective HSP70, antioxidant enzymes (heme oxygenase-1, superoxide dismutase and catalase) and autophagy machinery (LC3 and p62/SQSTM1) in aortic tissue. Conclusion: HSP90 inhibition protects from atherosclerosis in experimental diabetes through the induction of Nrf2-dependent cytoprotective mechanisms, reinforcing its therapeutic potential (AU)</dc:description>
<dc:creator>Egido, Jesus</dc:creator>
<dc:creator>Gomez Guerrero, Carmen</dc:creator>
<dc:creator>Lazaro, Iolanda</dc:creator>
<dc:creator>Recio, Carlota</dc:creator>
<dc:creator>Bernal, Susana</dc:creator>
<dc:creator>Oguiza, Ainhoa</dc:creator>
<dc:creator>Lopez Sanz, Laura</dc:creator>
<dc:language>en</dc:language>
<dc:description xml:lang="es">Introducción: Estrés oxidativo e inflamación son procesos clave en las complicaciones vasculares de la diabetes. La expresión de heat shock protein 90 (HSP90) en placas ateroscleróticas prolonga la inflamación, y su inhibición previene la aterosclerosis. Este trabajo investiga, en un modelo de aterosclerosis asociada a diabetes, si el efecto ateroprotector de la inhibición farmacológica de HSP90 está mediado por la inducción de mecanismos de defensa antioxidante dependientes del factor de transcripción nuclear factor erythroid-derived 2-like 2 (Nrf2). Métodos: Ratones deficientes en apolipoproteína E con diabetes por estreptozotocina se trataron durante 10 semanas con el inhibidor de HSP90 (17-dimetilaminoetilamino-demetoxigeldanamicina, 4mg/kg). Analizamos tamaño/composición de las placas, factores de transcripción y marcadores inflamatorios y antioxidantes. In vitro estudiamos macrófagos murinos bajo condiciones de hiperglucemia. Resultados: El inhibidor de HSP90 indujo activación de Nrf2 en aorta de ratones diabéticos (localizado en macrófagos y células de músculo liso) y en células en cultivo. La activación de Nrf2 junto con la inhibición de nuclear factor-¿B (NF-¿B) en las placas ateroscleróticas resultó en una reducción significativa del tamaño de la lesión y del componente inflamatorio (leucocitos y citocinas). Este efecto ateroprotector se vinculó con un aumento de la proteína citoprotectora HSP70, enzimas antioxidantes (hemoxigenasa-1, superóxido dismutasa y catalasa) y genes de autofagia (LC3 y p62/SQSTM1) en aorta de ratones tratados con el inhibidor de HSP90. Conclusión: La inhibición de HSP90 protege del desarrollo de aterosclerosis en la diabetes experimental a través de la inducción de mecanismos citoprotectores dependientes de Nrf2, lo que refuerza su potencial terapéutico (AU)</dc:description>
<dc:source>Clín. investig. arterioscler. (Ed. impr.);29(2): 51-59, mar.-abr. 2017. ilus, graf, tab</dc:source>
<dc:identifier>ibc-161015</dc:identifier>
<dc:title xml:lang="es">Interacción entre las vías HSP90 y Nrf2 en la aterosclerosis asociada a diabetes</dc:title>
<dc:subject>^d8994</dc:subject>
<dc:subject>^d841</dc:subject>
<dc:subject>^d50976^s22002</dc:subject>
<dc:subject>^d32101^s22031</dc:subject>
<dc:subject>^d32204^s22006</dc:subject>
<dc:subject>^d33519^s22079</dc:subject>
<dc:subject>^d979^s22079</dc:subject>
<dc:subject>^d1351^s22031</dc:subject>
<dc:subject>^d32204^s22002</dc:subject>
<dc:subject>^d3942^s22032</dc:subject>
<dc:subject>^d50504^s22054</dc:subject>
<dc:type>article</dc:type>
<dc:date>201704</dc:date>
</metadata>
</record>
</ibecs-document>
